US Biotech Advances Cancer Trial at Milan's European Institute of Oncology

Delcath Systems, a Nasdaq-listed interventional oncology specialist, announced this week that the first patient has been dosed in its global Phase 2 clinical trial at the European Institute of Oncology in Milan. The trial evaluates HEPZATO, a treatment targeting liver-dominant metastatic breast cancer. According to BioSpace, the trial's launch at IEO signals the institute's standing among international pharmaceutical developers seeking European trial sites for advanced oncology programmes. The move reflects a pattern of US biotech firms anchoring multi-national studies in Lombardy's research institutions.

Milan's position as a hub for clinical research has deepened over the past five years, driven by the city's concentration of world-class research hospitals and regulatory expertise. The European Institute of Oncology, one of Italy's leading cancer research facilities, has become a preferred site for Phase 2 and Phase 3 trials by international developers. BioSpace's coverage of the Delcath announcement did not specify the trial's total patient cohort or timeline, but the selection of IEO for the European launch underscores the institute's credibility with US pharmaceutical companies navigating European regulatory pathways.

For Lombardy's pharmaceutical sector, which has positioned itself as Italy's innovation engine, the trial represents both validation and competitive leverage. The region's pharmaceutical and biotech firms benefit from proximity to world-class research institutions and a regulatory environment that attracts international sponsors. The presence of advanced clinical infrastructure also creates spillover effects: contract research organizations, clinical trial management firms, and pharmaceutical consultancies cluster around major trial sites. Delcath's choice of Milan—rather than London, Berlin, or Paris—reflects the city's growing appeal as a site for cutting-edge oncology research, even as Italy's overall share of European clinical trials remains modest.